medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2018, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2018; 16 (4)

Quality of Life and Psychological Factors in Latin American Patients with Psoriasis: A Cross-Sectional Study

Mejía-Jiménez M, Jiménez-Tamayo SB, Alvaran-Florez L, Segura-Cardona DA, Londoño-García Á, Vásquez-Trespalacios EM

Language: Spanish
References: 44
Page: 254-262
PDF size: 164.22 Kb.


ABSTRACT

Background: psoriasis is a chronic disease with a significant psychological impact and health care professionals should address its effects in life quality. We used a multidisciplinary approach, including dermatologists and psychologist, to characterize clinically and psychologically patients with psoriasis.
Methods: clinical and demographic data were collected in patients with psoriasis, also classified severity and quality of life using Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and the 36-item Short Form Survey (SF-36) questionnaire. Mood and anxiety were assessed by the State-Trait Anxiety Inventory (STAI), self-schematics by the Scheme Questionnaires (CIE), personality traits by the Personality Belief Questionnaire (PBQ-SF), and coping strategies by the modified Coping Strategies Scale (EEC-M).
Results: ninety-six patients were included, 45.8% had moderatedsevere psoriasis. The average DLQI score was 7.35 points, a 78.1% reported impact in quality of life. A statistically significant association was found between dermatologic quality of life and disease severity. Anxiety disorders predominate over depressive disorders, 59.4% of patients reported some level of family dysfunction. The most common personality disorders were schizoid, obsessive-compulsive, and passive-aggressive. Personality disorders associated with lower dermatologic quality of life index were obsessive-compulsive and passive-aggressive type. A significant association was found between lower quality of life and aggressive acting-out.
Conclusion: our study supports the role of a multidisciplinary approach for the treatment of psoriasis, from the physical standpoint, but also from a psychological health.


REFERENCES

  1. Gaviria C, Seidel A y Velásquez M, Epidemiología de la psoriasis. En González C, Londoño A y Castro L (eds.), Guías basadas en la evidencia para el manejo de la psoriasis en Colombia, 2012, pp. 23-4.

  2. González C y Castro LA, Caracterización epidemiológica de la psoriasis en el Hospital Militar Central, Rev Asoc Col Dermatol 2009; 17(1):11-7.

  3. Velez N, Bohórquez L y Corrales MF, Caracterización de los pacientes con psoriasis en tratamiento con fototerapia, Rev Asoc Col Dermatol 2011; 19:100-6.

  4. Puig L, Carrascosa JM, Carretero G, De la Cueva P, Lafuente-Urrez RF, Belinchón I et al., Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, Actas Dermo-Sifiliográficas 2013; 104(8):694-709.

  5. Sociedad Latinoamericana de Psoriasis, Consenso Latinoamericano de Psoriasis: Guías de Tratamiento, Dermatología Argentina 2010; 16(1):1-29.

  6. Parisi R, Symmons DPM, Griffiths CEM y Ashcroft DM, Global epidemiology of psoriasis: a systematic review of incidence and prevalence, J Invest Dermatol 2013; 133(2):377-85.

  7. Rachakonda TD, Schupp CW y Armstrong AW, Psoriasis prevalence among adults in the United States, J Am Acad Dermatol 2014; 70(3):512-6.

  8. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud P-A, Aractingi S et al., Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies, J Eur Acad Dermatol Venereol 2010; 24 Suppl 2:23-30.

  9. Armstrong AW, Harskamp CT y Armstrong EJ, The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies, Nutr Diabetes 2012; 2:e54.

  10. Armstrong AW, Harskamp CT y Armstrong EJ, The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies, J Hypertens 2013; 31(3):433-43.

  11. Ma C, Harskamp CT, Armstrong EJ y Armstrong AW, The association between psoriasis and dyslipidaemia: a systematic review, Br J Dermatol 2013; 168(3):486-95.

  12. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B et al., Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review, J Eur Acad Dermatol Venereol 2013; 27 Suppl 3:12-29.

  13. Sánchez-Carazo JL, López-Estebaranz JL y Guisado C, Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study), J Dermatol 2014; 41(8):673-8.

  14. Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B et al., Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool, J Invest Dermatol 2012; 132(4):1111-6.

  15. Ministerio de Salud y Protección Social, Estrategia nacional de respuesta integral frente al consumo de alcohol en Colombia, 2013. Disponible en: https://www.minsalud.gov.co/sites/rid/.../estrategia-nacional- alcohol-colombia.pdf.

  16. Secretaría Seccional de Salud y Protección Social de Antioquia, Situación del consumo de drogas en Antioquia: sistema único de indicadores sobre consumo de sustancias psicoactivas Colombia, 2014. Disponible en: www.odc.gov.co/.../CO03951213-suispa-consumo- drogas-antioquia-preliminar.pdf.

  17. Hayes J y Koo J, Psoriasis: depression, anxiety, smoking, and drinking habits, Dermatol Ther 2010; 23(2):174-80.

  18. Poikolainen K, Karvonen J y Pukkala E, Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis, Arch Dermatol 1999; 135(12):1490-3.

  19. Tobin AM, Higgins EM, Norris S y Kirby B, Prevalence of psoriasis in patients with alcoholic liver disease, Clin Exp Dermatol 2009; 34(6):698- 701.

  20. Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ y Griffiths CEM, Alcohol consumption and psychological distress in patients with psoriasis, Br J Dermatol 2008; 158(1):138-40.

  21. Gudjonsson JE y Elder JT, Psoriasis. En Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS y Leffell DJ (eds.), Fitzpatrick’s dermatology in general medicine, 7ª ed., Nueva York, McGraw-Hill Medical, 2012, pp. 169-93.

  22. Ministerio de Salud y Protección Social, Estudio nacional de consumo de sustancias psicoactivas en Colombia, 2013 Disponible en: https:// www.unodc.org/documents/colombia/2014/Julio/Estudio_de_Consumo_ UNODC.pdf.

  23. Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY et al., A systematic review of the use of quality of life instruments in randomised controlled trials of psoriasis, Br J Dermatol 2017; 176(3): 577-93.

  24. Kimball AB, Jacobson C, Weiss S, Vreeland MG y Wu Y, The psychosocial burden of psoriasis, Am J Clin Dermatol 2005; 6(6):383-92.

  25. Mease PJ y Menter MA, Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective, J Am Acad Dermatol 2006; 54(4):685-704.

  26. Zaragoza V, Pérez A, Sánchez JL, Oliver V, Martínez L y Alegre V, Long-term safety and efficacy of etanercept in the treatment of psoriasis, Actas Dermo-Sifiliográficas 2010; 101(1):47-53.

  27. Canarte C, Cabrera F, Palacios S, Valencia N y Narváez S, La psoriasis y la incidencia de patologías comórbidas en los pacientes de la Fundación Ecuatoriana de la Psoriasis (FEPSO) y del hospital Carlos Andrade Marín (IESS) durante el periodo 1993-2007, Congreso Nacional de Dermatología, Cuenca 2006; 2006 (documento oficial).

  28. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB et al., Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?, J Am Acad Dermatol 2000; 43(2 Pt 1):281-5.

  29. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mørk C et al., Quality of life in 6 497 Nordic patients with psoriasis, Br J Dermatol 2002; 146(6):1006-16.

  30. Trujillo AI, García D, Sagaró Delgado B y Díaz MA, Patogenia de la psoriasis a la luz de los conocimientos actuales, Rev Cuba Med 2001; 40(2):122-34.

  31. De Korte J, Mombers FMC, Sprangers MAG y Bos JD, The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review, Arch Dermatol 2002; 138(9):1221-27.

  32. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud P-A, Aractingi S et al., What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature, J Eur Acad Dermatol Venereol 2010; 24 Suppl 2:17-22.

  33. De Korte J, Sprangers MA, Mombers FM y Bos JD, Quality of life in patients with psoriasis: a systematic literature review, J Investig Dermatol Symp Proc 2004; 9(2):140-7.

  34. Rapp SR, Feldman SR, Exum ML, Fleischer AB y Reboussin DM, Psoriasis causes as much disability as other major medical diseases, J Am Acad Dermatol 1999; 41(3 Pt 1):401-7.

  35. Fortune DG, Main CJ, O’Sullivan TM y Griffiths CE, Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress, Br J Dermatol 1997; 137(5):755-60.

  36. Sampogna F, Tabolli S, Söderfeldt B, Axtelius B, Aparo U, Abeni D et al., Measuring quality of life of patients with different clinical types of psoriasis using the SF-36, Br J Dermatol 2006; 154(5):844-9.

  37. Nichol MB, Margolies JE, Lippa E, Rowe M y Quell J, The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis, PharmacoEconomics 1996; 10(6):644-53.

  38. Finlay AY y Khan GK, Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use, Clin Exp Dermatol 1994; 19(3):210-6.

  39. Mazzotti E, Barbaranelli C, Picardi A, Abeni D y Pasquini P, Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis, Acta Derm Venereol 2005; 85(5):409-13.

  40. Lundberg L, Johannesson M, Silverdahl M, Hermansson C y Lindberg M, Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity, Acta Derm Venereol 2000; 80(6):430-4.

  41. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D et al., Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis, Br J Dermatol 2003; 149(2):318-22.

  42. Bahmer JA, Kuhl J y Bahmer FA, How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria?, Acta Derm Venereol 2007; 87(4):317-24.

  43. Verhoeven EW, De Klerk S, Kraaimaat FW, Van de Kerkhof PC, De Jong EM y Evers AW, Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review, Acta Derm Venereol 2008; 88(3):211-18.

  44. Brufau RM, Corbalán J, Brufau C, Ramírez A y Limiñana RM, Estilos de personalidad en pacientes con psoriasis, Anales de Psicología 2010; 26(2):335-40.




2020     |     www.medigraphic.com